Trial Profile

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer with and Without Pembrolizumab

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LNS 8801 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Haematological malignancies; Lymphoma; Malignant melanoma; Mesothelioma; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Pancreatic cancer; Skin cancer; Solid tumours; Uterine cancer; Uveal melanoma
Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
Sponsors Linnaeus Therapeutics

Most Recent Events

13 Jul 2026 Planned End Date changed from 15 Dec 2027 to 15 Aug 2026.
13 Jul 2026 Status changed from recruiting to active, no longer recruiting.
13 Dec 2024 Planned End Date changed from 15 Dec 2024 to 15 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com